The Long Acting Injectables Market is estimated at US$21.5 billion in 2026 and is projected to grow at a CAGR of 14.9% to reach US$65.3 billion by 2034.
Relevant uses and settings include mental health care, hormonal therapy, infectious disease treatment, chronic disease management, hospital administration, and outpatient specialty programs. Commercial considerations include high formulation complexity, administration logistics, reimbursement pressure, and patient acceptance issues around injectable treatment pathways.
This product will be delivered within 1-3 business days.
Market Overview
The Long Acting Injectables Market covers injectable therapies formulated to provide extended drug release and reduce dosing frequency across psychiatric, infectious disease, endocrine, and other specialty treatment areas.Relevant uses and settings include mental health care, hormonal therapy, infectious disease treatment, chronic disease management, hospital administration, and outpatient specialty programs. Commercial considerations include high formulation complexity, administration logistics, reimbursement pressure, and patient acceptance issues around injectable treatment pathways.
Key Companies Analysed
- Johnson & Johnson
- Otsuka Pharmaceutical
- Eli Lilly
- AstraZeneca
- Teva Pharmaceutical
- Bristol Myers Squibb
- GSK
- Alkermes
- Biogen
- Viatris
- Pfizer
- Novartis
- Lundbeck
- AbbVie
- Dr. Reddy's Laboratories
- Sun Pharma
- Cipla
- Luye Pharma
- Hikma Pharmaceuticals
- Aurobindo Pharma
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Long Acting Injectables Market Overview
3. Long Acting Injectables Market Dynamics
4. Long Acting Injectables Market Strategic Analysis
5. Global Long Acting Injectables Market Size, Share and Forecast, 2025-2034
6. North America Long Acting Injectables Market Outlook to 2034
7. Europe Long Acting Injectables Market Outlook to 2034
8. Asia-Pacific Long Acting Injectables Market Outlook to 2034
9. Middle East and Africa Long Acting Injectables Market Outlook to 2034
10. South and Central America Long Acting Injectables Market Outlook to 2034
11. Long Acting Injectables Market Competitive Landscape
12. Appendix
Companies Mentioned
- Johnson & Johnson
- Otsuka Pharmaceutical
- Eli Lilly
- AstraZeneca
- Teva Pharmaceutical
- Bristol Myers Squibb
- GSK
- Alkermes
- Biogen
- Viatris
- Pfizer
- Novartis
- Lundbeck
- AbbVie
- Dr. Reddy's Laboratories
- Sun Pharma
- Cipla
- Luye Pharma
- Hikma Pharmaceuticals
- Aurobindo Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 21.5 Billion |
| Forecasted Market Value ( USD | $ 65.3 Billion |
| Compound Annual Growth Rate | 14.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
